Investigating preventive effects of oral 25-hydroxyvitamin D3 on COVID-19 in adults: A Randomized, Controlled Double-Blind Clinical Trial.

Tehran University of Medical Sciences0 个研究点目标入组 540 人开始时间: 待定最近更新: 2020年6月15日

试验速览

暂无简介。

•Non-infected with COVID-19 (based on WHO criteria)
•Older than 17 years old and younger than 76 years old
•No medications or disorders that would affect vitamin D metabolism
•Women must be not pregnant at baseline and during study
•Ability and willingness to give informed consent and comply with protocol requirements

•Ongoing treatment with pharmacologic doses of vitamin D, vitamin D metabolites or analogs
•Pregnant or lactating women
•Severe underlying diseases, such as an advanced malignant tumor, end-stage lung disease, etc.
•History of elevated serum calcium levels more than 10.6 mg/dl
•History of chronic hepatic, renal failure or patients with reduced kidney function, cancers, malabsorption syndrome, or granulomatous disorders such as Sarcoidosis or Tuberculosis
•Supplementation with over the counter formulations of vitamin D2 or vitamin D3
•Use of tanning bed or artificial UV exposure within the last two weeks
•Consuming medication affecting bone metabolism (anti-convulsants, anti-tuberculosis medication, cimetidine, theophylline, and cholestyramine)
•Following special diets such as vegetarian diet or consuming fortified products regularly
•A history of an adverse reaction to orally administered vitamin D, vitamin D metabolites or analogs
•Inability to give informed consent

发起方